Nanopath

Executive Summary

Nanopath is a molecular diagnostics company pioneering a novel point-of-care platform for women's health. Its core technology leverages surface plasmon resonance (SPR) to enable rapid, multiplexed detection of pathogens without requiring nucleic acid amplification, thereby reducing cost and complexity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Nanopath aims to democratize diagnostic access by delivering results in minutes at the point of care. The platform holds promise for addressing unmet needs in sexually transmitted infections, vaginal infections, and other conditions where timely diagnosis is critical. By eliminating the need for specialized lab infrastructure, Nanopath's solution could expand testing access in underserved and resource-limited settings, aligning with the growing trend toward decentralized diagnostics. Given its early stage as a private company, Nanopath has not yet commercialized a product. However, its innovative SPR-based approach represents a potential step-change in rapid diagnostics. The company's focus on women's health—a historically under-invested area—positions it favorably within a large and growing market. While still pre-revenue, Nanopath's technology has attracted interest from investors and strategic partners. Key upcoming catalysts include prospective clinical validation studies, regulatory milestones, and fundraising events that could accelerate development and commercialization.

Upcoming Catalysts (preview)

• Q4 2026Series B or Series A funding round closure70% success
• Q2 2027Clinical validation study results for lead indication (e.g., chlamydia/gonorrhea)55% success
• Q3 2027FDA Breakthrough Device designation or 510(k) submission40% success